Literature DB >> 11605090

Are African American patients at a higher risk for olanzapine-induced glucose intolerance?

J Ananth, S Gunatilake, S Aquino, V Bach, J Costa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11605090     DOI： 10.1007/s002130100862

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  9 in total

1.  Hyperglycemia and olanzapine.

Authors:  S K Ober; R Hudak; A Rusterholtz
Journal:  Am J Psychiatry       Date:  1999-06       Impact factor: 18.112

2.  Olanzapine-induced ketoacidosis with diabetes mellitus.

Authors:  J P Lindenmayer; R Patel
Journal:  Am J Psychiatry       Date:  1999-09       Impact factor: 18.112

3.  Olanzapine-induced elevation of plasma triglyceride levels.

Authors:  B B Sheitman; P M Bird; W Binz; L Akinli; C Sanchez
Journal:  Am J Psychiatry       Date:  1999-09       Impact factor: 18.112

4.  New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment.

Authors:  L E Goldstein; J Sporn; S Brown; H Kim; J Finkelstein; G K Gaffey; G Sachs; T A Stern
Journal:  Psychosomatics       Date:  1999 Sep-Oct       Impact factor: 2.386

5.  Diabetic ketoacidosis with olanzapine treatment.

Authors:  B Gatta; V Rigalleau; H Gin
Journal:  Diabetes Care       Date:  1999-06       Impact factor: 19.112

6.  Novel antipsychotics and new onset diabetes.

Authors:  D A Wirshing; B J Spellberg; S M Erhart; S R Marder; W C Wirshing
Journal:  Biol Psychiatry       Date:  1998-10-15       Impact factor: 13.382

7.  Hyperglycemia associated with olanzapine.

Authors:  M K Fertig; V G Brooks; P S Shelton; C W English
Journal:  J Clin Psychiatry       Date:  1998-12       Impact factor: 4.384

Review 8.  Physical and psychological consequences of weight gain.

Authors:  I Kawachi
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

Review 9.  Atypical antipsychotic drugs and long-term outcome in schizophrenia.

Authors:  P Weiden; R Aquila; J Standard
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384
  9 in total
  2 in total

Review 1.  Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.

Authors:  Kristina Melkersson; Marja-Liisa Dahl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Authors:  Virginia L Stauffer; Jennifer L Sniadecki; Kevin W Piezer; Jennifer Gatz; Sara Kollack-Walker; Vicki Poole Hoffmann; Robert Conley; Todd Durell
Journal:  BMC Psychiatry       Date:  2010-11-03       Impact factor: 3.630
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.